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Multiple sclerosisThe opposing immune functions of Treg and Th17 lymphocytes and the plasticity of Treg/Th17 differentiation,
has led us to investigate the effects of their ﬂuctuations and counterbalance in autoimmune condition ofmultiple
sclerosis (MS). Evaluation of Treg and Th17 frequency in peripheral blood of a group of relapsed MS patients,
showed a decrease in Treg/Th17 ratio compared to that of healthy controls. A reverse correlation between
these subsets was observed in controls but not in patient groups. Both Treg frequency and Treg/Th17 ratio
were negatively correlated with severity of symptoms. There was shown to be an enduring increase in Treg
frequency associated with MS disease.
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Multiple sclerosis (MS) is known as a neurotropic autoimmune dis-
ease where a coordinated attack of innate and adaptive immune cells
inﬂames the central nervous system (CNS), and interrupts signal trans-
duction through demyelinating (destruction of myelin cover) of the
nerve ﬁbers. Neurological symptoms may result from distinct attacks
(relapsing–remittingMS)or accumulate over time (progressive subtypes).
The ﬁrst clinical manifestation of relapsing–remitting MS (RR-MS) is the
clinically isolated syndrome (CIS). Most of the CIS patients are at high
risk for MS, but the deﬁnitive MS diagnosis depends on the collective
criteria of magnetic resonance imaging (MRI), cerebral–spinal ﬂuid (CSF)
analysis and clinical data (Polman et al., 2011).
In addition to precise central mechanisms in the thymus which are
responsible for removing the auto-reactive T cells, induction of regula-
tory T cells and suppression of effector T cells as themost important pe-
ripheral regulatory mechanisms, are crucial for establishing and
maintaining self-tolerance in the immune system. Defective suppres-
sion of auto reactive pathogenic T cells due to alterations in one or
more of these peripheral check points has been considered as a main
cause of autoimmunity in MS (Venken et al., 2010). Regulatory
T (Treg) cells, a speciﬁc suppressor subtype of CD4+T cells, aregy, School of Medicine, Isfahan
744-176, Iran. Tel.: +98 311
agozloo).
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way (natural Treg), or induced in the peripheral immune system organs
under peripheral regulatory mechanisms (inducible Treg). Both natural
and inducible Tregs are characterized by a high expression of IL-2 recep-
tor α-chain (CD25) on their surface, and a transcription factor named
Forkhead box P3 (FOXP3) in their nucleus which is considered as their
most exclusive lineage marker (Sakaguchi et al., 2010).
Th17 cells are a more recently discovered effector subset of CD4+ T
cells, characterized by IL-17A cytokine production. In contrast to Tregs,
Th17 cells play a potent pro-inﬂammatory role in the immune system,
through stimulating a range of inﬂammatory mediators including IL-9,
IL-17A, IL-17F, IL-21, IL-22, TNF and granulocyte–macrophage colony-
stimulating factor (GM-CSF), also provoking chemokine expression
and neutrophil recruitment. Besides Th17 effector function in defense
against extracellular pathogens, these cells can promote many autoim-
mune inﬂammatory conditions, unless they are efﬁciently controlled by
regulatory cells (Wilson et al., 2007).
Interestingly, Th17 and inducible Tregs, originate from common
naïve CD4+ T cell precursors in the peripheral immune system or-
gans under the inﬂuence of a key cytokine, transforming growth fac-
tor β1 (TGFβ1) (Weaver et al., 2006), although the full attainment of
pathogenic potential by effector Th17 cells is dependent on the other
cytokines such as IL-23 (McGeachy et al., 2007). Moreover, under
certain in vitro inﬂammatory conditions, differentiated regulatory T
cells have a tendency to be reprogrammed and convert to the inﬂam-
matory Th17 subset (Koenen et al., 2008). Therefore, with setting the
boundaries of mediation and regulation of inﬂammatory reactions,hts reserved.
Table 1
Clinical and demographic characteristics of study groups.
Normal controls CIS RR-MS
Age ± SD, year (range) 31.4 ± 9.1
(19–50)
30.6 ± 7.9
(17–42)
32.8 ± 7.7
(19–51)
Female/male (ratio)a 19/4 (4.67) 6/5 (1.20) 22/1 (22.00)
Disease duration ± SD,
month (range)
NA b1 (0–1) 56.3 ± 58.4
(6–252)
EDSS score ± SD (range) NA 2.37 ± 0.77
(1.5–3.5)
2.97 ± 1.22
(1.6–6.0)
Immuno-modulatory drugs No No IFNβ-a, IMb,
weekly
Total 23 11 23
a The women to men ratio in the patient groups overall is 28/6 (4.75) and is matched
with controls.
b Intra muscular injection.
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subset alone, is an imperative checkpoint in immune homeostasis.
The present study was conducted to evaluate Treg/Th17 ratio in pe-
ripheral blood of MS patients in context of both subset frequency
measurements.2. Methods
2.1. Human subjects
Peripheral blood sampleswere obtained fromMS patients attending
a MS outpatient's clinic and from age and sex matched healthy volun-
teers at Kashani University Hospital in Isfahan, Iran. According to the
McDonald diagnostic criteria for MS (Polman et al., 2011), the involved
patients were diagnosed as having either RR-MS or CIS, with a clinically
documented attack of neurological symptoms (relapse) within the last
2–7 days, but still were free of corticosteroids or other immunosup-
pressive treatments in the present attack. Relapse was deﬁned as the
appearance of one or more neurological abnormalities in both CIS and
RR-MS groups and worsening of pre-existing neurological symptoms
in RR-MS group, in the absence of any underlying infectious disease.
The abnormalities had to persist for more than 24 h after a period of
at least 30 days of disease stability to be considered as a new relapse.
All patients had white matter lesions on their brain and/or spinal cord
identiﬁed via MRI. Clinical severity of disease was measured by the
Kurtzke's Expanded Disability Status Scale (EDSS) scores (Kurtzke,
1994). All RR-MS patients had been previously treated with
interferon-β-a during the last remission, however patients who had re-
ceived a drug in the last 5 days were not included in this study. In the
CIS group, no patient had a history of receiving immuno-modulatory
treatments. Informed consents were obtained from all subjects. The
study was approved by the institutional review boards of Isfahan
University of Medical Sciences and the local ethics committee.2.2. Preparation and stimulation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized blood samples immediately following blood collection,
by density gradient centrifugation on lymphocyte cell separation
medium (Lymphodex; Inno-Train Diagnostik, Kronberg, Germany).
For Th17 assays, 2 × 106 PBMCs were stimulated in 1 mL RPMI
1640 medium (Gibco, Grand Island, NY, USA) supplemented with
10% FCS, for 6 h at 37 °C and 5% CO2 in the presence of 25 ng/mL
phorbol myristate acetate (PMA) and 1 μg/mL ionomycin (both
from Sigma-Aldrich, MO, USA). Cytokines were maintained inside
the cells by adding 1.5 μg/mL monensin (Sigma-Aldrich, MO, USA)
in the ﬁnal 4 h of stimulation.2.3. Surface and intracellular-staining of cells and analysis by ﬂow
cytometry
To identify Treg cells, 1 × 106 PBMCs were surface labeled within
2 h of isolation, with PerCP-Cy5.5 conjugated anti-human CD4 (clone
RPA-T4, eBioscience, CA, USA) and ﬂuorescein isothiocynate (FITC) con-
jugated anti-human CD25 (clone 2A3, BD Biosciences Pharminogen, CA,
USA) antibodies. Surface labelingwas followed by an overnight ﬁxation
with 4% w/v para-formaldehyde (PFA) in 4 °C and then washed with
0.1% w/v saponin. Permeabilization was performed by 0.1% w/v triton
(t-octylphenoxypolyethoxyethanol) X-100 solution (Sigma-Aldrich,
Steinheim, Germany) for 30 min at room temperature. All washing
buffers used after permeabilization contained 0.1% w/v saponin. Intra-
cellular staining was achieved by 60 minute incubation of perme-
abilized cells with a phycoerythrin (PE) labeled anti-FOXP3 antibody
(clone 236A/E7, eBioscience, CA, USA).
For detecting Th17 cells, cells were stimulated for 6 h as above, then
harvested, washedwith PBS, and surface-labeledwith PerCP-Cy5.5 con-
jugated anti-CD4 (clone RPA-T4, eBioscience, CA, USA). Intracellular cy-
tokine staining was conducted after 2 hour ﬁxation with 4% PFA and
then, 1 hour permeabilization with 0.1% w/v saponin solution. All
wash buffers used after permeabilization contained 0.1% w/v saponin.
Intracellular labeling was performed as above with anti-IL17a−FITC
(clone eBio64DEC17, eBioscience, CA, USA).
Isotype matched control antibodies (all from eBioscience) were
used in parallel for PerCP-Cy5.5, PE and FITC mouse IgG1 K isotype
antibodies to determine nonspeciﬁc binding of antibodies, also to
help ﬁnd out the levels of background emittance and setting gates
and quadrants.
Flow cytometry was carried out using BD FACSCalibur instrument.
3–5 × 105 events were acquired from each sample tube, and lympho-
cytes were gated based on their side and forward light scatter charac-
teristics. Cell Quest analysis program (BD Biosciences, NSW, Australia)
was used to analyze acquired data. Complete blood cell count was de-
termined with hematology analyzer Sysmex XE2100 (Sysmex, Kobe,
Japan) and the absolute counts of lymphocytes were used for calculat-
ing absolute numbers of Treg and Th17 cells.
2.4. Statistical analysis
Data were analyzed using IBM SPSS Statistics version 20.0 (SPSS
Inc., San Francisco, CA, USA). The statistical differences between con-
trol and MS patient groups were evaluated using the nonparametric
two-tailed Mann–Whitney ranked sum test. Data were verbalized as
mean ± standard error of the mean. Spearman's rank correlations
were used to assess the relationships between variables. P value of
b0.05 was considered signiﬁcant.
3. Results
3.1. Study groups
Clinical and demographic characteristics of patients and controls
are summarized in Table 1. CIS and RR-MS patient groups were signif-
icantly different in gender ratio, disease duration, EDSS score, and
history of IFN-β therapy.
3.2. Reduced frequency of Tregs in MS relapses
Treg cells were delineated as CD4+CD25+FOXP3+ cells. The CD4+
population of lymphocytes was gated (Fig. 1-A), and frequency of
CD25+FOXP3+ cells in this population was evaluated (Fig. 1-B). The
mean percentage of these cells in healthy subjects was signiﬁcantly
higher than in all patients groups, also it was slightly but not signiﬁ-
cantly higher in RR-MS patients compared with CIS group, (Table 2)
(Fig. 1-D).
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Table 2
Frequencies, ratios and absolute counts of studied subpopulations in controls and patient groups.
Subpopulations Controls
N = 23
All patients
N = 34
RR-MS patients
N = 23
CIS patients
N = 11
Treg (%) 1.12 ± 0.68 0.51 ± 0.20⁎⁎⁎ 0.53 ± 0.20⁎⁎⁎ 0.47 ± 0.20⁎⁎
Th17 (%) 0.34 ± 0.16 1.33 ± 0.67⁎⁎⁎ 1.45 ± 0.71⁎⁎⁎ 1.08 ± 0.52⁎⁎⁎
Treg/Th17 ratio 4.22 ± 3.32 0.51 ± 0.49⁎⁎⁎ 0.46 ± 0.35⁎⁎⁎ 0.60 ± 0.62⁎⁎⁎
CD4+CD25+cells (%) 3.04 ± 1.02 2.25 ± 0.84 ⁎⁎ 2.43 ± 0.81 1.87 ± 0.80⁎⁎
FOXP3+cells (%) in CD4+CD25Highcells 80.83 ± 11.97 62.05 ± 8.05⁎⁎⁎ 62.85 ± 8.47⁎⁎⁎ 60.37 ± 7.17⁎⁎⁎
Lymphocyte count (×103/mm3) 2.09 ± 0.51 1.74 ± 0.60⁎ 1.65 ± 0.62⁎ 1.94 ± 0.58
Treg count (×103/mm3) 12.33 ± 10.25 4.93 ± 2.81⁎⁎⁎ 4.77 ± 1.74⁎⁎⁎ 5.24 ± 4.05⁎⁎
Th17 count (×103/mm3) 5.58 ± 3.16 16.42 ± 8.58⁎⁎⁎ 16.57 ± 7.51⁎⁎⁎ 16.11 ± 10.63⁎⁎⁎
⁎ P b 0.05, in comparison with controls.
⁎⁎ P b 0.01, in comparison with controls.
⁎⁎⁎ P b 0.001, in comparison with controls.
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activated Tcells that transiently express FOXP3 but do not have sup-
pressive function, we captured the highest expression of CD25
through gating on top 0.5% of CD4+CD25+lymphocytes (Fig. 2). The
mean percentage of FOXP3+cells in CD4+CD25high population in
healthy subjects was signiﬁcantly greater when compared to RR-MS,
CIS, and total patients. No signiﬁcant difference was observed be-
tween RR-MS and CIS patients.
A higher frequency of CD4+CD25+Tcells was seen in controls in
comparison with CIS and total patients. The observed difference of
CD4+CD25+Tcells between RR-MS and CIS patients was not signiﬁ-
cant (P = 0.060).
3.3. Increased frequency of Th17 cells in MS relapse
To identify the Th17 subset, the capacity of these cells to produce
detectable amounts of IL-17A cytokine upon stimulation, was used in
ﬂow cytometry analysis. CD4+IL-17+Tcells in the lymphocyte gate
were considered as Th17 cells and their frequency was compared be-
tween study groups (Fig. 1-C). Th17 cells showed greater frequency
in the patient groups in comparison to healthy controls (Fig. 1-D).
Also the frequency of these cells in RR-MS group was slightly elevated
as compared to CIS patients, although this difference was not signiﬁ-
cant (Table 2).
3.4. Multiple fold decrease in Treg/Th17 ratio in relapsed MS
To investigate the relation between changes of two subpopula-
tions, the Treg/Th17 ratio in each blood sample was calculated. The
Treg/Th17 ratio was shown to be almost nine and seven folds greater
in control subjects than in RR-MS patients and CIS patients, respec-
tively (Table 2) (Fig. 1-D). Although both Treg and Th17 subsets fre-
quency are a bit elevated in RR-MS in comparison with CIS patients
(both not signiﬁcantly as mentioned above), the Treg/Th17 ratio is
slightly less in RR-MS, but this difference was not signiﬁcant
(Table 2).
3.5. Negative correlation of Th17 frequency with FOXP3 expression in
CD4+CD25HighTcells in healthy subjects but not in MS patients
A strong inverse relationship was found between the frequency of
Th17 cells and FOXP3 expression in CD4+CD25HighTcells in total
study cohort (P b 0.001, R = −0.519). When the healthy and patient
groups were separately analyzed, the inverse correlation disappearedFig. 1. Peripheral Treg and Th17 cells. (A) Gating strategy is demonstrated. The lymphocyt
(Right), then the CD4+ population in the lymphocyte region was gated in R2 (Left). (B, C) Re
the percentage of related population in each quadrant. (B) Tregs were identiﬁed as CD25+F
cells in lymphocyte gate. (D) Treg and Th17 cells mean frequency and ratio in study group
Th17 ratio is signiﬁcantly correlated with symptoms severity indicated by EDSS score.in patients and remained signiﬁcant in healthy subjects (P = 0.008,
R = -0.536) (Fig. 3).
3.6. Treg frequency and Treg/Th17 balance, but not Th17 frequency is
closely correlated with patients' EDSS scores
We also examined the effects of Treg and Th17 frequency both dis-
tinctly and in context of their balance, on the severity of present at-
tack in MS patients. The EDSS score as a clinical scale of symptom
severity was used for this purpose. There was a signiﬁcant inverse
correlation between EDSS and both Treg frequency (P = 0.003,
R = -0.501) and Treg/Th17 ratio (P = 0.017, R = -0.418) in MS pa-
tients (Fig. 1-E). As expected, the relationship tended toward positive
for Th17 cells, but the correlation was not signiﬁcant (P = 0.215,
R = +0.226). There wasn't any signiﬁcant relationship between
EDSS and other scalable variables like age and disease duration.
3.7. Tregs frequency and FOXP3 expression by CD4+CD25HighTcells are
signiﬁcantly increased with disease duration enhancement
A positive correlation was observed between disease duration and
Treg frequency (P = 0.034, R = +0.443) and FOXP3 expression in
CD4+CD25HighTcells (P = 0.038, R = +0.435) in RR-MS patients.
All CIS patients were newly diagnosed, however when they were
added to RR-MS for this analysis, the observed positive correlation
between disease duration and Treg frequency, also FOXP3 expression
in CD4+CD25HighTcells became more signiﬁcant and less strong (P =
0.024, R = +0.387 and P = 0.020, R = +0.398, respectively). There
wasn't any signiﬁcant correlation between disease duration and Th17
frequency or Treg/Th17 ratio. Control and patient groups were tested
for possible relationships between age and cell frequencies and no
signiﬁcant correlation was observed.
3.8. Absolute counts of lymphocytes and lymphocyte subtypes
From the statistical point of view, total changes in lymphocyte
numbers may signiﬁcantly affect the frequency of subtypes. To refute
such error in the frequency results, the absolute count of lymphocyte
subsets were also calculated in each blood sample as the product of
subset frequency in lymphocyte gate and the absolute number of
lymphocytes. The mean lymphocyte absolute numbers, gained by
hem-analyzer complete blood cell counts, is shown in Table 2. The
differences between controls and all patients (P = 0.049) and con-
trols and RR-MS patients (P = 0.02) were signiﬁcant and other
groups didn't show a signiﬁcant difference in the total count ofes were gated in R1 region based on their side and forward light scattering properties
presentative dot plots from one control and one patient are shown. Numbers represent
OXP3+ cells in CD4+ lymphocytes gate. (C) Th17 cells were identiﬁed as CD4+ IL17A+
s. Only comparisons between all patients and controls are shown. *P b 0.001 (E) Treg/
Fig. 2. Percentages of FOXP3 expression in CD4+CD25HighestTcells in representative patient and control samples. (A)The top 0.5% of CD25High cells is gated on CD4+CD25+ lympho-
cytes. (B) The percentages of FOXP3 expressing cells in these gates are shown. The overlaid histograms are the same samples stained with isotype matched control antibodies.
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niﬁcantly less and the mean count of Th17 cells was signiﬁcantly
more than controls. There wasn't any signiﬁcant difference in Treg
and Th17 absolute counts between RR-MS and CIS patients.
4. Discussion
There have been controversial reports about the frequency of regu-
latory Tcells and pro-inﬂammatory Th17 cells in peripheral blood of
MS patients, with the majority of the discrepancy in Treg data. While
most previous studies have been conducted on clinically stable state
of disease (Putheti et al., 2004; Venken et al., 2007; Cosentino et al.,
2012; Praksova et al., 2012), more questions emerge around such ﬂuc-
tuations in acute attacks of MS. Of the few studies that have involved
relapsed-MS, some reported a compensatory peripheral increase of
Tregs approaching normal levels in comparison with remission state,
while others showed no difference between both states of relapse and
remission and health (Feger et al., 2007; Edwards et al., 2011). Studying
documented relapses of MS, our Treg frequency data suggests a de-
creased number of Tregs, also lower expression of their functionality
marker FOXP3, and signiﬁcant association of both with severity of
new attack.
We have also examined the CD4+CD25+ population, ignoring
FOXP3 staining. While a higher frequency of these cells was seen in
healthy subjects versus all patients and CIS patients groups, this differ-
ence was not signiﬁcant in the case of RR-MS patients. Consistent
with these results, other groups who studied RR-MS patients only in
relapse, also reported no signiﬁcant change in the percentages of
CD4+CD25+cells (Putheti et al., 2004; Haas et al., 2005; Braitch et al.,
2009). A key preference of our study to previous ones is intracellular
staining of the transcription factor FOXP3 as the most exclusive marker
for Tregs. It has been shown that the expression levels of FOXP3 is di-
rectly correlated with Treg suppressive activity (Fontenot et al., 2003;
Venken et al., 2007), and a deﬁciency exists in suppressive function of
CD4+CD25HighTregs despite their normal count, during both relapse
and remission in MS patients (Haas et al., 2005; Venken et al., 2008).
Also, the lower Treg frequency in remitted MS has been evident onlywith FOXP3 staining (Venken et al., 2007). In a more recent study,
Bjerg et al. have shown a dichotomy in Treg frequency among remitting
RR-MS patients (Bjerg et al., 2012). While they observed no change in
FOXP3+Tregs frequency in total patients against all controls, when
patients were segregated in two groups with FOXP3+Treg percentages
higher and lower than the median in total controls, the two patient
groups were signiﬁcantly different from each other, also from their
matched controls. The lower Treg frequency was related to the higher
median of disease severity score indicated by EDSS. Although they
have included just remitting patients, considering the elevated EDSS
scores in MS relapses versus remission states, our results of lower
Treg frequency in relapsed MS versus health are in agreement with
this study. Also, the observation of a signiﬁcant reverse correlation be-
tween Treg percentages and EDSS scores in our study, represents
lower Treg frequency relates to more severity of symptoms in
relapsed MS.
The observed Treg frequency enhancement as a function of disease
duration has also been reported previously (Venken et al., 2008).
Considering the reports of Treg augmentation in the elderly (Gregg et
al., 2005; Rosenkranz et al., 2007) along with an early immune-
senescence in MS disease like other autoimmunities (Hug et al., 2003;
Thewissen et al., 2007), this Treg enhancement may occur as a conse-
quence of premature activation of mechanisms which normally cause
immune-senescence in the elderly. Naturally, T cell generation declines
with the age due to thymus involution, as the ﬁrst appearing aspect of
immune-senescence. Considering the accelerated immune-senescence
inMS autoimmunity, reduced repertoire of naïve T cells with increasing
disease duration may cause memory Tregs enrichment by comparison.
Entirely in line with this hypothesis, our study has shown a signiﬁcant
decrease in total lymphocyte count in RR-MS patients and a slight but
non-signiﬁcant decline in newly diagnosed CIS patients in comparison
with healthy subjects. Our ﬁndings are in agreement with previous re-
ports of reduced frequency of naïve Tregs in early stages and enhanced
memory Tregs in later-stageMS (Venken et al., 2008). Therewas no sig-
niﬁcant correlation between cell frequencies and age in either control or
patient groups. Additionally, therewas no correlation in cell frequencies
between IFN-β treated and untreated patient groups. Nevertheless, it is
Fig. 3. FOXP3+Tregs and Th17 cells frequency relation curves in study groups. The neg-
ative correlation in healthy bodies is lost in MS patients. All subjects (N = 57); healthy
controls (N = 23); MS patients (N = 34).
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tion may be affected by direct relation between disease duration and
the length of time to be in IFN-β therapy as previously shown
(Praksova et al., 2012).
Consistent with our results, an obvious increase in Th17 cells in
PBMCs of relapsed MS patients has been reported by others (Durelli et
al., 2009; Edwards et al., 2010; Peelen et al., 2011). However in another
study, a highly signiﬁcant increase of Th17cells in CSF, despite a
non-signiﬁcant increase in the peripheral blood, has been shown in
relapsed-MS versus remission and other neurological diseases
(Brucklacher-Waldert et al., 2009). The difference in PBMC evaluation
results may be due to comparison between relapsed MS and remitted
patients, also other neurological diseases, but not healthy subjects.
Although we did not evaluate CSF samples as well, considering the dis-
ruption of blood–brain barrier (BBB) as a main and early phenomenon
inMS pathogenesis (Morales et al., 2006), it is interpretable that the en-
hancement of Th17 cells in peripheral blood, could result in relative en-
hancement in the CSF. In addition, one of themainmechanisms through
which Th17 cells promote CNS inﬂammation, is through a breakdown in
the BBB (Kebir et al., 2007).The hallmark cytokine of Th17 subset, IL-17A was used for identi-
fying this subset. However, new evidences are emerging about the
role of other cytokines in the pathogenicity of Th17 cells. Studies in
experimental autoimmune encephalomyelitis (EAE), an animal
model of MS, have revealed that Th17 pathogenicity is independent
of IL-17A production. Indeed, the cytokine GM-CSF, is the only
T cell-cytokine which is necessary for susceptibility to EAE induction.
This cytokine is produced by Th1, Th2 and Th17 cells and is known as
a critical element in both TH1 and TH17 pathogenicity. Pathogenic
TH17 cells which are re-stimulated with IL-23, have been shown to
produce higher amounts of GM-CSF than non-pathogenic Th17 cells
(El-Behi et al., 2011).
In addition to extending previous knowledge of both subset dis-
crepancies in MS relapses, our study clariﬁed a reverse relationship
between the percentages of FOXP3 expressing cells in CD4+CD25High
population and Th17 cell frequency in circulation (Fig. 3). Interest-
ingly, this correlation tends to be lost in patients, when they are an-
alyzed separately from healthy subjects. It reveals that in healthy
individuals, Th17 cells differentiation is effectively controlled by
FOXP3+Tregs, so higher frequency of one subset is associated with
lower counts of the other subset. In contrast, in relapsed-MS the in-
crease of Th17 cells was offset by the enhancement in the number
of FOXP3+Tregs, but the Treg portion was not sufﬁcient to regulate
the enhanced induction of Th17 phenotype under the pathologic
MS. Comparable to our results, Peelen et al. have reported a signiﬁ-
cant direct correlation between another regulatory phenotype
(CD39+Tregs) and Th17 cells in remitted-MS which has been lost
in relapsed disease (Peelen et al., 2011).
In accordance with a deﬁcient regulatory function in MS patients
indicated by many studies (Venken et al., 2007; Venken et al., 2008;
Smolders et al., 2009), it is to be expected that higher frequency of
FOXP3+Tregs does not result in a lower frequency of Th17 cells in in-
dividual patients. It is also conceivable that effector Th17 cells have an
unusual resistance to suppression by Tregs in MS patients. Such resis-
tance has been reported in other immune-pathogenic conditions
(Schneider et al., 2008; Chauhan et al., 2009), although to the best
of our knowledge it has not yet been investigated in MS. The reversal
of the Treg/Th17 ratio, from more than fourfold higher frequency of
Tregs in healthy subjects to an approximately one-half prevalence
in proportion to Th17 cells in relapsed MS, is the other remarkable as-
pect of our results. This shift in ratios is in full accord with the above
mentioned probabilities of Treg deﬁciency or Th17 cell resistance in
these patients. Also, considering the plasticity in T-helper subsets
(Koenen et al., 2008; Weaver and Hatton, 2009; d'Hennezel and
Piccirillo, 2012), it may be the case that the inﬂammatory conditions
in MS promotes more conversion of differentiated Treg cells to Th17
phenotype. However, the rate of IL-17 production by FOXP3+ Tcells
in MS patients versus healthy subjects is unclear. It has been shown
that epigenetic modiﬁcations induced by histone deacetylase en-
zymes has an extreme inﬂuence on the emergence of IL-17 producing
FOXP3+ Tcells (Koenen et al., 2008; Weaver and Hatton, 2009). Be-
side the certiﬁed role of these enzymes in MS disease (Gray and
Dangond, 2006; Kazantsev and Thompson, 2008), this ﬁnding implies
a connection between Treg-Th17 plasticity and MS pathogenesis.
The Treg/Th17 balance has been shown to be similarly disturbed in
other autoimmune and inﬂammatory conditions, with decreasing
Tregs versus increasing Th17 cells (Eastaff-Leung et al., 2010; Li et al.,
2010; Ma et al., 2010; Liu et al., 2011; Shen et al., 2011). While a previ-
ous study in MS patients reported no signiﬁcant difference in this ratio
despite increased Th17 and decreased Treg frequency in these patients
and a positive correlation between Treg and Th17 frequencies in the
total study cohort (Edwards et al., 2011). The inconsistencies may be
partly explained by dissimilarities in study design, MS types and
courses, and case volumes, as the study involved progressive MS,
RR-MS and CIS in remission, and a lower number of relapsed patients.
Even so, the need for more investigation is undeniable.
112 A. Jamshidian et al. / Journal of Neuroimmunology 262 (2013) 106–112In conclusion, our results suggest an important role for Treg/Th17
imbalance in MS relapses. There are still many issues which remain to
be better clariﬁed about this disease: 1) Treg efﬁciency in control of
Th17 cells, 2) the contribution of Th17 resistance to Treg suppressive
effect, and 3) Treg to Th17 conversion and relative rates of IL-17 pro-
duction by FOXP3+Tcells. In addition to these clues for basic research,
our data conﬁrms the changes in Treg/Th17 balance as an informative
biomarker for evaluating or comparing the effectiveness of MS thera-
pies, and highlights the Treg-Th17 interaction as a target for new
therapeutic approaches.
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